Michael D. Olp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael D. Olp has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Brian Christopher Smith
Department of Biochemistry, Medical College of Wisconsin, Milwaukee, USA
3 shared publications - Raymundo Nuñez
Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
3 shared publications - Christopher G. Goetz
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
2 shared publications Guanming Jiao
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana, USA
2 shared publications- Karina L. Bursch
Structural Genomics Unit , Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine , Medical College of Wisconsin , Milwaukee , Wisconsin , USA , mcw.edu
2 shared publications - Adam J. Kanack
Department of Laboratory Medicine & Pathology Mayo Clinic Rochester Minnesota USA
1 shared publication
Latest Publications
- Open Access
- 10 February 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (3) , 108289
Multivalent nucleosome scaffolding by bromodomain and extraterminal domain tandem bromodomains
- 10 February 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (3) , 108289
Open AccessMultivalent nucleosome scaffolding by bromodomain and extraterminal domain tandem bromodomains
- Open Access
HLA-C Peptide Repertoires as Predictors of Clinical Response during Early SARS-CoV-2 Infection
The human leukocyte antigen (HLA) system plays a pivotal role in the immune response to viral infections, mediating the presentation of viral peptides to T cells and influencing both the strength and specificity of the host immune response. Variations in HLA genotypes across individuals lead to differences in susceptibility to viral infection and severity of illness. This study uses observations from the early phase of the COVID-19 pandemic to explore how specific HLA class I molecules affect clinical responses to SARS-CoV-2 infection. By analyzing paired high-resolution HLA types and viral genomic sequences from 60 patients, we assess the relationship between predicted HLA class I peptide binding repertoires and infection severity as measured by the sequential organ failure assessment score. This approach leverages functional convergence across HLA-C alleles to identify relationships that may otherwise be inaccessible due to allelic diversity and limitations in sample size. Surprisingly, our findings show that severely symptomatic infection in this cohort is associated with disproportionately abundant binding of SARS-CoV-2 structural and non-structural protein epitopes by patient HLA-C molecules. In addition, the extent of overlap between a given patient’s predicted HLA-C and HLA-A peptide binding repertoires correlates with worse prognoses in this cohort. The findings highlight immunologic mechanisms linking HLA-C molecules with the human response to viral pathogens that warrant further investigation.
Open AccessHLA-C Peptide Repertoires as Predictors of Clinical Response during Early SARS-CoV-2 Infection
The human leukocyte antigen (HLA) system plays a pivotal role in the immune response to viral infections, mediating the presentation of viral peptides to T cells and influencing both the strength and specificity of the host immune response. Variations in HLA genotypes across individuals lead to differences in susceptibility to viral infection and severity of illness. This study uses observations from the early phase of the COVID-19 pandemic to explore how specific HLA class I molecules affect clinical responses to SARS-CoV-2 infection. By analyzing paired high-resolution HLA types and viral genomic sequences from 60 patients, we assess the relationship between predicted HLA class I peptide binding repertoires and infection severity as measured by the sequential organ failure assessment score. This approach leverages functional convergence across HLA-C alleles to identify relationships that may otherwise be inaccessible due to allelic diversity and limitations in sample size. Surprisingly, our findings show that severely symptomatic infection in this cohort is associated with disproportionately abundant binding of SARS-CoV-2 structural and non-structural protein epitopes by patient HLA-C molecules. In addition, the extent of overlap between a given patient’s predicted HLA-C and HLA-A peptide binding repertoires correlates with worse prognoses in this cohort. The findings highlight immunologic mechanisms linking HLA-C molecules with the human response to viral pathogens that warrant further investigation.
- Open Access
- 7 March 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (4) , 107146
Cancer-associated polybromo-1 bromodomain 4 missense variants variably impact bromodomain ligand binding and cell growth suppression
- 7 March 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (4) , 107146
Open AccessCancer-associated polybromo-1 bromodomain 4 missense variants variably impact bromodomain ligand binding and cell growth suppression
- Open Access
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S705-S706
Abstract 1294: Cancer-associated missense mutations in the tumor suppressor Polybromo-1 variably affect protein stability and function
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S705-S706
Open AccessAbstract 1294: Cancer-associated missense mutations in the tumor suppressor Polybromo-1 variably affect protein stability and function
- Open Access
- 3 February 2022
- Published by Wiley in ChemBioChem
- Vol. 23 (6) , e202100633
Chemical Regulation of the Protein Quality Control E3 Ubiquitin Ligase C‐Terminus of Hsc70 Interacting Protein (CHIP)
The ubiquitin ligase C‐terminus of Hsc70 interacting protein (CHIP) is an important regulator of proteostasis. Despite playing an important role in maintaining proteostasis, little progress has been made in developing small molecules that regulate ubiquitin transfer by CHIP. Here we used differential scanning fluorimetry to identify compounds that bound CHIP. Compounds that bound CHIP were then analyzed by quantitative ubiquitination assays to identify those that altered CHIP function. One compound, MS.001, inhibited both the chaperone binding and ubiquitin ligase activity of CHIP at low micromolar concentrations. Interestingly, we found that MS.001 did not have activity against isolated U‐box or tetratricopeptide (TPR) domains, but instead only inhibited full‐length CHIP. Using in silico docking we identified a potential MS.001 binding site on the linker domain of CHIP and mutation of this site rendered CHIP resistant to MS.001. Together our data identify an inhibitor of the E3 ligase CHIP and provides insight into the development of compounds that regulate CHIP activity.
- 3 February 2022
- Published by Wiley in ChemBioChem
- Vol. 23 (6) , e202100633
Open AccessChemical Regulation of the Protein Quality Control E3 Ubiquitin Ligase C‐Terminus of Hsc70 Interacting Protein (CHIP)
The ubiquitin ligase C‐terminus of Hsc70 interacting protein (CHIP) is an important regulator of proteostasis. Despite playing an important role in maintaining proteostasis, little progress has been made in developing small molecules that regulate ubiquitin transfer by CHIP. Here we used differential scanning fluorimetry to identify compounds that bound CHIP. Compounds that bound CHIP were then analyzed by quantitative ubiquitination assays to identify those that altered CHIP function. One compound, MS.001, inhibited both the chaperone binding and ubiquitin ligase activity of CHIP at low micromolar concentrations. Interestingly, we found that MS.001 did not have activity against isolated U‐box or tetratricopeptide (TPR) domains, but instead only inhibited full‐length CHIP. Using in silico docking we identified a potential MS.001 binding site on the linker domain of CHIP and mutation of this site rendered CHIP resistant to MS.001. Together our data identify an inhibitor of the E3 ligase CHIP and provides insight into the development of compounds that regulate CHIP activity.